BioCorRx (BICX) Equity Average (2016 - 2025)
BioCorRx (BICX) has disclosed Equity Average for 15 consecutive years, with -$5.6 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 53.32% to -$5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.6 million through Dec 2025, up 53.32% year-over-year, with the annual reading at -$11.7 million for FY2025, 5.76% down from the prior year.
- Equity Average hit -$5.6 million in Q4 2025 for BioCorRx, down from -$159422.5 in the prior quarter.
- In the past five years, Equity Average ranged from a high of -$159422.5 in Q1 2025 to a low of -$12.1 million in Q4 2024.
- Historically, Equity Average has averaged -$7.5 million across 5 years, with a median of -$7.5 million in 2022.
- Biggest five-year swings in Equity Average: tumbled 150.02% in 2021 and later skyrocketed 98.47% in 2025.
- Year by year, Equity Average stood at -$6.4 million in 2021, then decreased by 20.66% to -$7.7 million in 2022, then dropped by 24.74% to -$9.6 million in 2023, then fell by 25.56% to -$12.1 million in 2024, then surged by 53.32% to -$5.6 million in 2025.
- Business Quant data shows Equity Average for BICX at -$5.6 million in Q4 2025, -$159422.5 in Q1 2025, and -$12.1 million in Q4 2024.